Page 12 - Syncona Ltd News Today

Investegate announcements from Syncona Limited, Syncona leads $87 million financing of Clade

TRADING UPDATES: BATM signs new deal; Synectics wins two projects | Financial News

Investegate announcements from Syncona Limited, Achilles reports Second Quarter 2021 Results

LONDON BRIEFING: BP promises buybacks and 4% annual dividend hikes Tue, 3rd Aug 2021 08:12 (Alliance News) - BP on Tuesday lifted its quarterly dividend and unveiled a USD1.4 billion share buyback, while dangling the prospect of more of both to shareholders. The oil major swung to an underlying replacement cost profit for the second quarter of USD2.80 billion from a USD6.68 billion loss a year ago. It also marked an improvement from the first quarter of 2021, when it recorded profit of USD2.63 ...

Investegate announcements from Syncona Limited, Autolus to present additional data in AUTO1

Investegate announcements from Syncona Limited, Director/PDMR Shareholding

  - Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -     London, UK 11 May 2021 - Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2021 and recent business...

-3.90%   -  Morgan Advanced Materials PLC  (MGAMM.L)  Learn Forex: GBP Higher in Overnight Trade The British pound is the strongest major overnight, despite Nicola Sturgeon touting another Scottish referendum following the SNP’s fourth consecutive win. One would have expected the pound to suffer with the prospect of a new referendum, yet as the SNP fell just short of an outright majority, traders don’t appear to see it as an issue just yet. Boris Johnson condemned a second referendu...

7 May 2021 | 07:21am StockMarketWire.com - Syncona Ltd, a healthcare company focused on founding, building and funding a portfolio of global leaders in life science, has noted that its portfolio company, Gyroscope Therapeutics Holdings plc has postponed plans for its initial public offering in light of the current market conditions. "In light of market conditions, we have decided to postpone our planned initial public offering," said Khurem Farooq, Gyroscope Therapeutics’ chief executive offi...

Tel: +44 (0) 20 3727 1000   About Syncona Synconas purpose is to invest to extend and enhance human life. We do this by founding, building and funding a portfolio of global leaders in life science, to deliver transformational treatments to patients in areas of high unmet need.   Our strategy is to found, build and fund companies around exceptional science to create a dynamic portfolio of 15-20 globally leading healthcare businesses for the benefit of all o...